Assessment of Approved COVID-19 Vaccines

​Given the broad and extensive coverage by the media and the scientific literature on how the Pharma/Biotech world is doing in the development and deployment of COVID-19 Vaccines in 2020-2021, Refana decided to take an objective, systematic look at the 'current state' of the approved COVID-19 vaccine world, to assess how these vaccines were doing in the fight against the COVID-19 Pandemic.  As a result, this 'White Paper' addresses six key questions:
​

1. How are the currently approved COVID-19 vaccines doing overall in the fight against the Pandemic?
2. How are they doing against the emerging 'Variants of Concern' (Alpha - UK, Beta - South Africa, Gamma - Brazil and Delta - India) vs. the original Wuhan virus?
3. What are the key side-effects of each approved COVID-19 vaccine
4. How well are the approved COVID-19 vaccines doing as far as levels and lengths of immunity and the need for further Booster shots?
5. How have these vaccine manufacturers' done as they transitioned from development to production of their vaccines?
6. How have other factors - Government-driven vaccine diplomacy, vaccine hoarding/equity issues, and vaccine hesitancy - impacted the roll-out of these approved Vaccines?

Refana summarized its findings in a short-form outline style to make these insights more accessible.  Refana have also provided detailed Appendices with more specific info to support the summary outline, plus a detailed listing of all source links to the original articles and research papers that drove the assessment.

This material is not meant to be a detailed scientific review of the approved vaccines, but more of a summary of the ongoing findings related to the approved vaccines with respect to these six key questions, based on the substantial amount of reporting that has been published world-wide during the COVID-19 Pandemic.  As such - and as an objective assessment of where things stand - Refana believes this material represents a good consolidated reference document on the current 'State of the Art' for the approved COVID-19 vaccines.    

Since this is a highly dynamic situation, Refana is referring to this White Paper as the June 2021 Release V1.0. Refana intends to regularly update this material with the latest info on all approved COVID-19 vaccines on a periodic basis.

Access White Paper

​Since this is a highly dynamic situation, Refana is referring to this White Paper as the June 2021 Release V1.0. Refana intends to regularly update this material with the latest info on all approved COVID-19 vaccines on a periodic basis.

Back to Blog

---